IRD

insider transactions

Opus Genetics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 90d

-1.7M

0 buy · 1.7M sell

Net value · 90d

-$7.6M

$0 in · $7.6M out

Sentiment · 90d

Net selling

0% buying · 100% selling

Open-market trades · 90d

0 buy · 1.7M sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Sell·S
May 18, 26

Foundation Fighting Blindness Retinal Degeneration Fund / Foundation Fighting Blindness, Inc.

Director

$7.4M

1.7M sh · $4.35

Own -31%
Sell·S
Apr 23, 26

Benjamin R Yerxa KEY

President

$39.1K

7.5K sh · $5.24

Own -1%
Sell·S
Apr 23, 26

Joseph K Schachle

Chief Operating Officer

$24.5K

4.7K sh · $5.22

Own -2%
Sell·S
Apr 23, 26

Rabourn Amy Zaremba

Head of Fin. Quality Assurance

$8.5K

1.6K sh · $5.20

Own -1%
Sell·S
Apr 23, 26

George Magrath KEY

Chief Executive Officer

$49.6K

9.5K sh · $5.22

Own -1%
Sell·S
Apr 23, 26

Ashwath Jayagopal

Chief Scientific & Dev. Ofc.

$39.2K

7.5K sh · $5.19

Own -1%
Grant·A
Apr 20, 26

Richard J Rodgers

Director

$0

24.4K sh

Own +8%
Grant·A
Apr 20, 26

James S J Manuso

Director

$0

24.4K sh

Own +8%
Grant·A
Apr 20, 26

Cam Gallagher

Director

$0

24.4K sh

Own +1%
Grant·A
Apr 20, 26

Susan Benton

Director

$0

24.4K sh

Own +11%
Grant·A
Apr 20, 26

Sean Ainsworth

Director

$0

24.4K sh

Own +8%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 18, 2026	Foundation Fighting Blindness Retinal Degeneration Fund / Foundation Fighting Blindness, Inc.	Director	Sell S	1.7M	-31%	$4.35	$7.4M
Apr 23, 2026	Benjamin R Yerxa KEY	President	Sell S	7.5K	-1%	$5.24	$39.1K
Apr 23, 2026	Joseph K Schachle	Chief Operating Officer	Sell S	4.7K	-2%	$5.22	$24.5K
Apr 23, 2026	Rabourn Amy Zaremba	Head of Fin. Quality Assurance	Sell S	1.6K	-1%	$5.20	$8.5K
Apr 23, 2026	George Magrath KEY	Chief Executive Officer	Sell S	9.5K	-1%	$5.22	$49.6K
Apr 23, 2026	Ashwath Jayagopal	Chief Scientific & Dev. Ofc.	Sell S	7.5K	-1%	$5.19	$39.2K
Apr 20, 2026	Richard J Rodgers	Director	Grant A	24.4K	+8%	—	$0
Apr 20, 2026	James S J Manuso	Director	Grant A	24.4K	+8%	—	$0
Apr 20, 2026	Cam Gallagher	Director	Grant A	24.4K	+1%	—	$0
Apr 20, 2026	Susan Benton	Director	Grant A	24.4K	+11%	—	$0
Apr 20, 2026	Sean Ainsworth	Director	Grant A	24.4K	+8%	—	$0

About IRD insider trading

This page tracks insider transactions for Opus Genetics, Inc. (IRD) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.